Please assess the completion status of the following clinical trial:

Trial Title: Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Adolescents aged 12 to 18 years~* Patients meeting the criteria for mild to moderate depression according to the DSM-IV scale~* Physical and laboratory examination at baseline compatible with study criteria~* ECG at baseline compatible with study criteria~* Score of at least 40 on the Children's Depression Rating Scale - Revised (CDRS-R) at baseline~Exclusion Criteria:~* Patients with psychosis, bi-polar disease, schizophrenia or significant developmental disorder~* Patients with epilepsy~* Patients with a history of alcohol or substance abuse in the past year~* Initiation of psychotherapy or behavioral therapy in the 2 months prior to screening or during the study.~* Patients who have previously failed to respond to SSRI's or SRNI's~* Patients who have been treated with antidepressants within 2 weeks of screening (4 weeks if fluoxetine)~* Patients with a contraindication to taking either Remotiv or fluoxetine or taking medication contraindicated when taking Remotiv or fluoxetine

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): hypericum 250mg tablets twice daily for 8 weeks
- B (Type: ACTIVE_COMPARATOR): fluoxetine 20mg - 40mg daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).